摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(1R)-1-phenylethyl]pyrrolidin-2-one | 60737-24-8

中文名称
——
中文别名
——
英文名称
1-[(1R)-1-phenylethyl]pyrrolidin-2-one
英文别名
1-((R)-α-methylbenzyl)-2-oxopyrrolidine;1-((R)-1-phenylethyl)pyrrolidin-2-one;1-(1R-phenyl-ethyl)-pyrrolidin-2-one
1-[(1R)-1-phenylethyl]pyrrolidin-2-one化学式
CAS
60737-24-8
化学式
C12H15NO
mdl
——
分子量
189.257
InChiKey
NEGMKRHJNDHTOS-SNVBAGLBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    20.3
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    1-[(1R)-1-phenylethyl]pyrrolidin-2-one甲烷磺酸 作用下, 以 甲苯 为溶剂, 反应 6.0h, 以92%的产率得到2-吡咯烷酮
    参考文献:
    名称:
    Simple and efficient cleavage of the N-(1-phenylethyl) unit of carboxamides with methanesulfonic acid
    摘要:
    Cleavage of the N-(1-phenylethyl) unit of carboxamides using less than 1 equiv of MsOH in refluxing toluene was found to be simple and very efficient leading to the desired amides in good to excellent yields, and also proved to be more effective compared with reductive methods using hydrogen Sources, or acid hydrolysis reagents Such as TFA and TsOH. The method selectively cleaved only the N-(1-phenylethyl) group of N-benzyl-N-(1-phenylethyl)amides. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetlet.2006.01.019
  • 作为产物:
    描述:
    γ-丁内酯R(+)-alpha-甲基苄胺 在 silica gel 作用下, 以 乙酸乙酯 为溶剂, 反应 54.0h, 生成 1-[(1R)-1-phenylethyl]pyrrolidin-2-one
    参考文献:
    名称:
    Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
    摘要:
    本发明涉及一种新型的取代哌啶衍生物,其化学式为(1),其立体异构体和药学上可接受的盐,其可用作组胺受体拮抗剂和速激肽受体拮抗剂。这样的拮抗剂可用于治疗过敏性鼻炎,包括季节性鼻炎和鼻窦炎;炎性肠病,包括克罗恩病和溃疡性结肠炎;哮喘;支气管炎;以及呕吐。
    公开号:
    US06211199B1
点击查看最新优质反应信息

文献信息

  • [EN] QUINOLONE ANTIBACTERIAL AGENTS<br/>[FR] AGENTS ANTIBACTERIENS A BASE DE QUINOLONE
    申请人:WARNER LAMBERT CO
    公开号:WO2005026165A1
    公开(公告)日:2005-03-24
    Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.
    公开了式I的化合物及其制备方法。进一步公开了制备式I生物活性化合物的方法,以及包括式I化合物的药用可接受组合物。本文公开的式I化合物可用于各种应用,包括用作抗菌剂。
  • Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases
    申请人:——
    公开号:US20010034343A1
    公开(公告)日:2001-10-25
    The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula 1 and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.
    本发明涉及一种新颖的4-(1H-苯并咪唑-2-基)[1,4]二氮杂环庚烷生物及其立体异构体,以及其药学上可接受的盐,其作为组胺受体拮抗剂和速激肽受体拮抗剂具有用途。这些拮抗剂在过敏性鼻炎的治疗中有用,包括季节性鼻炎和鼻窦炎;炎症性肠病,包括克罗恩病和溃疡性结肠炎;哮喘;支气管炎;以及呕吐。
  • Substituted 4-(1H-benzimidazol-2-yl)&lsqb;1,4&rsqb;diazepanes useful for the treatment of allergic disease
    申请人:Aventis Pharmaceuticals Inc.
    公开号:US06194406B1
    公开(公告)日:2001-02-27
    The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula (1): and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.
    本发明涉及新颖的4-(1H-苯并咪唑-2-基)[1,4]二氮杂环庚烷生物的化合物(1)及其立体异构体,以及其药学上可接受的盐,这些化合物可用作组胺受体拮抗剂和速激肽受体拮抗剂。这些拮抗剂在过敏性鼻炎的治疗中很有用,包括季节性鼻炎和鼻窦炎;炎症性肠病,包括克罗恩病和溃疡性结肠炎;哮喘;支气管炎;以及呕吐。
  • [EN] INHIBITORS OF HISTONE DEMETHYLASES<br/>[FR] INHIBITEURS D'HISTONES DÉMÉTHYLASES
    申请人:EPITHERAPEUTICS APS
    公开号:WO2015153498A1
    公开(公告)日:2015-10-08
    Compounds of the form in which Q is selected from -COOH -CH=NR12, -W, -CH2NHR13, -CH=0 and -CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
    Q被选择为-COOH、-CH=NR12、-W、-CH2NHR13、-CH=0和-CH(OR17)2形式的化合物,能够调节组蛋白去甲基化酶(HDMEs)的活性,这些化合物对于预防和/或治疗基因组失调参与病因学的疾病,如癌症等,以及这些化合物的配方和使用方法是有用的。
  • NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANTI-BACTERIALS
    申请人:Ropp Sandrine
    公开号:US20090221565A1
    公开(公告)日:2009-09-03
    A subject of the invention is the compounds of formula (I): in which either R 1 represents H, OH, NH 2 , —(CH 2 ) m —NR a R b (m=0.1 or 2), R a and R b represent H, linear, branched or cyclic (C 1 -C 6 ) alkyl, (C 3 -C 6 ) cycloalkyl-(C 3 -C 6 )— alkyl, R c , S(O) 2 R c , C(O)R c , S(O) 2 R d or C(O)R d ; or R a and R b with N form an R c radical; R c represents a saturated, unsaturated or 5- or 6-members aromatic ring, containing 1 to 4 heteroatoms chosen from N, O and S, optionally substituted; R d represents a linear, branched or cyclic (C 1 -C 6 ) alkyl, optionally substituted by 1 to 4 halogens; or R 1 represents R c or CHR e R c or CHR e R d ; R e represents H, OH, NH 2 , NH—(C 1 -C 6 )-alk or N-(C 1 -C 6 )-alk 2 , or NH—(C 1 -C 7 )-acyl or NHR c ; R 2 represents H, (CH 2 ) m —NR a R b , R c , CHR e R c or CHR e R d , and R′ 2 represents H; it being understood that R 1 and R 2 cannot at the same time be H or that R 1 and R 2 or R 2 and R 1 cannot be one (CH 2 ) m —NR a R b or R c or H and the other one OH, or one H and the other one NH 2 , or one H and the other one (CH 2 ) m —NR a R b in which R a and R b represent H or alkyl or C(O)R d , in which R d represents an unsubstituted alkyl or cycloalkyl; or R 1 has the above definition except H and R 2 and R′ 2 together represent gem dialkyl or alkyl-oxime, or R 2 and R′ 2 represent respectively R c or R d and OH, NH 2 , NHR c or NHR f , R f being a (C 1 -C 7 ) acyl radical; or R 1 represents H and R 2 and R′ 2 together represent alkyl-oxime or one represents R c and the other one represents OH, NH 2 , NHR c or NHR f ; n is 0 or 1; R 3 and R′ 3 represent H or (C 1 -C 6 ) alkyl optionally substituted by 1 to 3 halogens or R 3 represents (C 1 -C 6 ) alkoxy carbonyl and R′ 3 represents H; R4 represents methyl optionally substituted by halogen; R 5 represents H, (C 1 -C 6 ) alkyl or (C 7 -C 12 ) arylalkyl; R 6 represents H, fluorine, NO 2 , CF 3 or CN; in the form of enantiomers or mixtures, as well as their salts with acids and bases; their preparation and their application as anti-bacterials, in both human and veterinary medicine.
    本发明的一个主题是化合物的公式(I):其中R1代表H、OH、NH2、—(CH2)m—NRaRb(m=0、1或2);Ra和Rb代表H、直链、支链或环状(C1-C6)烷基、(C3-C6)环烷基-(C3-C6)烷基、Rc、S(O)2Rc、C(O)Rc、S(O)2Rd或C(O)Rd;或Ra和Rb与N形成一个Rc基团;Rc代表饱和、不饱和或含有1至4个N、O和S中的杂原子的5-或6-成员芳香环,可选地取代;Rd代表直链、支链或环状(C1-C6)烷基,可选地取代1至4个卤素;或R1代表Rc或CHReRc或CHReRd;Re代表H、OH、NH2、NH—(C1-C6)-烷基或N-(C1-C6)-烷基2,或NH—(C1-C7)-酰基或NHRc;R2代表H、( )m—NRaRb、Rc、CHReRc或CHReRd,而R′2代表H;R1和R2不能同时为H,或者R1和R2或R2和R1不能一个为( )m—NRaRb或Rc或H,另一个为OH,或一个为H,另一个为NH2,或一个为H,另一个为( )m—NRaRb,其中Ra和Rb代表H或烷基或C(O)Rd,其中Rd代表未取代的烷基或环烷基;或R1具有上述定义,除了H,R2和R′2一起表示双取代烷基或烷基氧,或者R2和R′2分别表示Rc或Rd和OH、NH2、NHRc或NHRf,其中Rf是(C1-C7)酰基基团;或R1代表H,R2和R′2一起表示烷基氧,或一个表示Rc,另一个表示OH、NH2、NHRc或NHRf;n为0或1;R3和R′3表示H或可选地取代1至3个卤素的(C1-C6)烷基,或R3表示(C1-C6)烷氧羰基,R′3表示H;R4表示可选地取代的甲基;R5表示H、(C1-C6)烷基或(C7-C12)芳基烷基;R6表示H、NO2CF3或CN;以对映体或混合物形式存在,以及它们与酸和碱形成的盐;它们的制备以及它们作为抗菌剂在人类和兽医学中的应用。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫